IASO Bio’s Fucaso NDA Accepted by Hong Kong DOH for Relapsed/Refractory Multiple Myeloma
China-based IASO Bio announced that a New Drug Application (NDA) for its BCMA-targeted chimeric antigen...
Company
Innovent Biologics’ IBI363 Receives FDA Fast-Track Designation for sqNSCLC
China-based Innovent Biologics, Inc. (HKG: 1801) announced that it has received another fast-track designation from...
Tianyi Medical Acquires Bellco’s CRRT Filter Business for EUR11.99m
Tianyi Medical (SHE: 301097), a Ningbo-based developer of Class III medical consumables, has announced plans...
Konruns Pharmaceutical’s KC1036 Enters Phase II Trial for Ewing’s Sarcoma in Adolescents
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) announced the first patient dosing in a Phase...
Hengrui Pharma Submits Ivarmacitinib Ointment for AD Treatment Approval
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced the submission of a marketing filing for...
Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology
In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...
Beijing Wanjie Medical Device Completes Near-Hundred Million Yuan B-Round Financing
Beijing Wanjie Medical Device Co., Ltd. recently announced the successful completion of a B-round financing...
Pharmaceutical Giants Race to Integrate DeepSeek AI for Efficiency Gains
On February 14, China’s stock market saw a significant upsurge in the AI pharmaceuticals sector,...
LinkZill Completes Multi-Million-Dollar A-Round Financing Led by ProximaVentures
Hangzhou LinkZill Technology Co., Ltd. has recently completed a multi-million-dollar A-round financing, exclusively led by...
Bristol Myers Squibb’s Opdualag Fails to Meet Primary Endpoint in Melanoma Study
US pharmaceutical major Bristol-Myers Squibb (BMS, NYSE: BMY) provided an update on the RELATIVITY-098 study...
Hengrui’s Vunakizumab Receives NMPA Approval for nr-axSpA Treatment
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received another clinical trial...
GE Healthcare Posts 1% Annual Revenue Growth in 2024 Financials
US medical device and life sciences giant GE Healthcare Technologies Inc. (NASDAQ: GEHC) released its...
Betta Pharma Files for EMA Approval of ALK Inhibitor Ensartinib
Betta Pharmaceuticals (SHE: 300558) announced the initiation of a market approval filing with the European...
Lee Kai and Yangshun Partner on Polyvinyl Alcohol Embolization Microspheres
Chinese companies Shanghai Lee Kai Technology Co., Ltd (Kai Medtech) and Hangzhou Yangshun Medical Technology...
Nanos Medical Raises Over RMB300m to Boost Otolaryngology Device Lead
China-based Nanos Medical (Shanghai) Limited, an otolaryngology device maker, has reportedly raised over RMB300 million...
SciClone’s Vibativ Approved by NMPA for HABP/VABP Treatment
China-based SciClone Pharmaceuticals Inc. announced that it has received market approval from the National Medical...
Trinomab’s Antitetanus mAb Injection TNM002 Approved by NMPA
China-based Trinomab Biotech Co., Ltd has received market approval for its antitetanus toxin monoclonal antibody...
Accropeutics Doses First Patient in AC-101 Phase Ib UC Study
Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...
Sanofi and J&J’s E. coli Vaccine Fails Phase III Study
France-based Sanofi (NASDAQ: SNY) and US giant Johnson & Johnson’s (J&J, NYSE: JNJ) vaccine candidate...
Antengene’s Xpovio Included in Taiwan’s NHI Drug List for Myeloma Treatment
China-based biopharma Antengene Corp., Ltd (HKG: 6996) announced that its Xpovio (selinexor), the world’s first...